MDWD - MediWound soars 18% after late-stage NexoBrid study met endpoints

MediWound (MDWD) jumps 17.6% premarket after announcing positive topline results from its Phase 3 pediatric clinical study (CIDS - Children Innovation Debridement Study) with NexoBrid to treat children with severe thermal burns, evaluating the efficacy and safety compared with standard-of-care ((SOC)). The trial enrolled 145 pediatric patients. The study met its three primary endpoints with a high degree of statistical significance.NexoBrid demonstrated a significant reduction in time to achieve complete eschar removal compared with patients treated with SOC (median time to complete eschar removal - NexoBrid: 0.99 days vs. SOC: 5.99 days, p=0.0008) and significant reduction in wound area requiring surgical excision (surgical need) (NexoBrid: 1.5% vs. SOC: 48.1%, p<0.0001) while demonstrating non-inferiority to SOC in quality of scars.The study also met certain secondary endpoints showing statistically significant reduction in the incidence of surgical excision and reduction in need for autograft in deep partial burns compared with SOC (NexoBrid: 25.93% (21/81) vs. SOC:

For further details see:

MediWound soars 18% after late-stage NexoBrid study met endpoints